Silence Therapeutics (SLN) loses 28.8% in 4 weeks, here's why a trend reversal may be around the corner
Silence Therapeutics PLC Sponsored ADR (SLN) has been beaten down lately with too much selling pressure. While the stock has ...
Model output · Signal date 2026-10-16
Silence Therapeutics Plc (SLN) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5121 stocks scored
Rank correlation · 90D
13.0%
Spearman, 357 dates
Market Cap
$563M
small-cap · #60 of 60 peers
Summary
Silence Therapeutics Plc (SLN) stock forecast summary
Our AI ranks Silence Therapeutics Plc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Silence Therapeutics Plc is a small-cap company with a market capitalization of $563M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For SLN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 13.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -10.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.4%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SLN included.
Follow SLN freePrice
SLN price chart and AI forecast
Cross-section · 2026-10-15
How SLN ranks among 5121 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Silence Therapeutics Plc (SLN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | SLN | Rank |
|---|---|---|
| Market Cap | $563M | 60/60 |
| P/B Ratio | 14.63x | 13/42 |
| EPS | $-0.53 | – |
| Book Value/Share | $0.64 | – |
| Revenue/Share | $0.01 | – |
| FCF/Share | $-0.70 | – |
Profitability & Margins
| Metric | SLN | Rank |
|---|---|---|
| ROIC | -72.9% | 41/46 |
| Gross Margin | 69.8% | 28/36 |
| Operating Margin | -9023.4% | 38/39 |
| EBT Margin | -7919.6% | 45/46 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | SLN | Rank |
|---|---|---|
| Current Ratio | 7.42x | 15/59 |
| D/E Ratio | 1.77x | 15/48 |
| Financial Leverage | 2.77x | 14/48 |
| Working Capital | $82M | 52/59 |
Cash Flow
| Metric | SLN | Rank |
|---|---|---|
| Operating Cash Flow | -$42M | 40/59 |
| Free Cash Flow | -$42M | 33/50 |
| Capital Spending | $0.00M | 1/50 |
| FCF/Sales | -5583.4% | 41/42 |
| CapEx/Sales | 0.4% | 34/42 |
Operational Efficiency
| Metric | SLN | Rank |
|---|---|---|
| Asset Turnover | 0.01x | 39/40 |
| Fixed Assets Turnover | 0.6x | 40/41 |
Income Statement
| Metric | SLN | Rank |
|---|---|---|
| Total Revenue | $760K | 46/46 |
| Operating Income | -$68M | 31/51 |
| R&D Expense | $48M | 56/58 |
| Cost of Goods Sold | $90K | 37/37 |
Dividend & Shareholder Information
| Metric | SLN | Rank |
|---|---|---|
| Shares Outstanding | 60M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $94M | 88.6% of assets |
| Cash & Short-term Investments | $72M | 67.7% of assets |
| Total Liabilities | $68M | 63.9% of assets |
Quarterly Financial Reports
SLN quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Silence Therapeutics Plc (SLN) industry peers
Companies classified under the same SEC industry code as Silence Therapeutics Plc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SLN Silence Therapeutics Plc | ▲ | $563M |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $610.38B |
| ABBV Abbvie Inc. | ▶ | $500.75B |
| MRK Merck & Co., Inc. | ▲ | $358.21B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $258.35B |
| ABT Abbott Laboratories | ▼ | $182.04B |
| NVO Novo Nordisk A S | ▼ | $174.29B |
| PFE Pfizer Inc | ▶ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $123.73B |
| SNY Sanofi | ▼ | $99.33B |
| GSK Gsk Plc | ▼ | $98.90B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.32B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▲ | $24.33B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.67B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.94B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.92B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $13.12B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $12.26B |
| ELAN Elanco Animal Health Inc | ▼ | $11.76B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.85B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.62B |
| CYTK Cytokinetics Inc | ▲ | $8.89B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.47B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.26B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.33B |
| ABVX Abivax S.A. | ▼ | $7.26B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.73B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.24B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.15B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| BLTE Belite Bio, Inc | ▲ | $6.00B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.95B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.35B |
| ERAS Erasca, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.89B |
| MANE Veradermics, Inc | ▲ | $4.81B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.17B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.15B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $3.97B |
Where SLN sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Silence Therapeutics Plc (SLN) stock news
Silence Therapeutics (SLN) upgraded to buy: Here's why
Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend ...
Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FAQ
Silence Therapeutics Plc (SLN) stock forecast FAQ
What is the Silence Therapeutics Plc (SLN) stock forecast?
Our AI ranks Silence Therapeutics Plc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Silence Therapeutics Plc stock predictions?
For SLN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 13.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -10.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Silence Therapeutics Plc forecasts updated?
Silence Therapeutics Plc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Silence Therapeutics Plc's industry peers?
60 issuers in our coverage, SLN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.